Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17633822 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2NFKB1TP53HPGDL3MBTL1 | |
| SCHEMBL5508324 | 0.82 | ALDH1A1 (0.70) | SMN1; SMN2NFKB1TP53HPGDALDH1A1 | |
| SCHEMBL11196763 | 0.81 | ALDH1A1 (0.64) | SMN1; SMN2NFKB1TP53ALDH1A1KCNH2 | |
| SCHEMBL6572409 | 0.80 | NPC1 (0.71) | SMN1; SMN2NPC1NFKB1TP53RAB9A | |
| SCHEMBL135088 | 0.79 | ALDH1A1 (0.62) | SMN1; SMN2NFKB1TP53MAPK1L3MBTL1 | |
| SCHEMBL5502874 | 0.79 | SMN1; SMN2 (0.79) | SMN1; SMN2NFKB1TP53HPGDL3MBTL1 | |
| SCHEMBL4347123 | 0.78 | RAB9A (0.68) | SMN1; SMN2NPC1NFKB1TP53RAB9A | |
| SCHEMBL12368426 | 0.78 | ALDH1A1 (0.65) | SMN1; SMN2NFKB1TP53HPGDL3MBTL1 | |
| SCHEMBL12893243 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1NFKB1TP53RAB9A | |
| SCHEMBL7527418 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1NFKB1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-20220347126-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11406607-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021203136-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-20180185305-A1 | An Amino Thiol for Use in the Treatment of an Infection Caused by the Bacterium Mycobacterium Spp | NOVABIOTICS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| EP-3307259-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | Novabiotics Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017212249-A1 | MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017212239-A1 | TREATMENT OF DRUG-RESISTANT MICROBIAL INFECTIONS | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348254-A1 | MICROPARTICLES | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20170348253-A1 | Treatment of Drug-Resistant Microbial Infections | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | SMN1; SMN2 2770/4885NPC1 339/4885NFKB1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.